Needham & Company analyst Gil Blum reiterated a Buy rating and $75.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE